- Home
- CII vs ESPR Comparison
CII vs ESPR Comparison
Compare CII & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CII | ESPR |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 898.5M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | CII | ESPR |
|---|---|---|
| Price | $23.41 | $3.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.67 |
| AVG Volume (30 Days) | 78.8K | ★ 4.9M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 6.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $303,802,000.00 |
| Revenue This Year | N/A | $26.11 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.83 |
| 52 Week Low | $16.76 | $0.69 |
| 52 Week High | $19.81 | $4.13 |
Technical Indicators
Market Signals| Indicator | CII | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 51.07 |
| Support Level | $23.14 | $3.63 |
| Resistance Level | $23.60 | $3.89 |
| Average True Range (ATR) | 0.31 | 0.19 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 35.58 | 20.00 |
Price Performance
Historical ComparisonAbout CII Blackrock Capital and Income Fund Inc.
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its objective is to provide total return through a combination of current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its total assets in a portfolio of equity securities of U.S. and foreign issuers.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.